BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $92.2 million in its second quarter.

The Boulder, Colorado-based company said it had a loss of $1.15 per share. Losses, adjusted to extinguish debt, were $1.11 per share.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.02 per share.

The biopharmaceutical company posted revenue of $39.9 million in the period, also falling short of Street forecasts. Four analysts surveyed by Zacks expected $44.7 million.

Clovis shares have decreased 40% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.23, a fall of 34% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS

Automated Insights, source Associated Press News